← Leaderboards
Ingunn Margarete Stromnes
University Of Minnesota
$4,130,375
Attributed
$4,130,375
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $877.8K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,130,375 · 2
By mechanism
R01$4,130,375 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Minnesota
Same institution · by research overlap
- Masato Yamamoto$9,316,402
- Branden S Moriarity$9,306,595
- Julia Davydova$3,953,014
- Douglas Yee$35,505,227
- Mark J Osborn$748,457
Others in their field
Other Emerging Leaders on “Neoplasm Metastasis”
- Rachana Agarwal · Leidos Biomedical Research, Inc.$15,241,462
- Mark Raymond Nelson · Hennepin Healthcare Research Institute$6,702,147
- Samuel F Bakhoum · Weill Medical Coll Of Cornell Univ$6,006,178
- Vesteinn Thorsson · Institute For Systems Biology$5,781,130
- Andrew Josef Ewald · Johns Hopkins University$5,735,880
- Kevin L. Gardner · Columbia University Health Sciences$5,645,546
Research focus
Neoplasm MetastasisPancreatic Cancer PatientsMediatingMyeloid CellsMalignant Neoplasm Of PancreasNeoplastic CellImmunotherapyMalignant NeoplasmsEngineered T CellsMortalityAffinityAnimal ModelAnimalsIn VivoEffective TherapyImmuneDiagnosisCancer EtiologyAntigen-Specific T CellsCellsCell PhysiologyMesothelinAntitumor EffectPancreatic Ductal Adenocarcinoma
Grant awards (13)
Mechanisms of immunotherapy response and resistance in pancreatic ductal adenocarcinoma$431,993
R01 · FY2025 · CA · contact PI
Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma$354,563
R01 · FY2025 · CA · contact PI
Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma$91,282
R01 · FY2025 · CA · contact PI
Mechanisms of immunotherapy response and resistance in pancreatic ductal adenocarcinoma$410,395
R01 · FY2024 · CA · contact PI
Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma$336,835
R01 · FY2024 · CA · contact PI
Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma$86,718
R01 · FY2024 · CA · contact PI
Mechanisms of immunotherapy response and resistance in pancreatic ductal adenocarcinoma$423,354
R01 · FY2023 · CA · contact PI
Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma$347,471
R01 · FY2023 · CA · contact PI
Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma$91,282
R01 · FY2023 · CA · contact PI
Mechanisms of immunotherapy response and resistance in pancreatic ductal adenocarcinoma$423,354
R01 · FY2022 · CA · contact PI
Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma$347,471
R01 · FY2022 · CA · contact PI
Mechanisms of immunotherapy response and resistance in pancreatic ductal adenocarcinoma$431,094
R01 · FY2021 · CA · contact PI
Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma$354,563
R01 · FY2021 · CA · contact PI